Breaking News

Karyopharm, Clinipace Enter Preferred Provider Pact

April 10, 2014

Clinipace to employ digital CRO model

Karyopharm Therapeutics, Inc. has entered into a preferred provider agreement with Clinipace Worldwide for the management of several clinical programs for oncology, wound healing, and other diseases. Clinipace will provide services under its digital CRO model aimed at accelerating a personalized approach to targeted therapies through collaboration, higher data quality, and reduced development costs.
  
“It is our mission to foster scientific creativity with pioneering technologies and developmental approaches within an innovative culture,” said Sharon Shacham, Ph.D., MBA, Karyopharm’s founder, president and chief scientific officer. “By partnering with a like-minded technology-driven company like Clinipace, we believe we can help accelerate our first-in-class small molecule modulators into effective targeted therapeutics for life threatening conditions.”
 
“As tailored therapies such as those Karyopharm have under development become more prominent, drug developers must find increasingly innovative ways to help bring their products to market in the most effective and efficient manner,” said Jeff Williams, chief executive officer and co-founder, Clinipace Worldwide. “Working with a technology-enabled digital CRO (dCRO) provides our clients with a significant level of information sharing that helps increase collaboration, improves data quality, and reduces their overall development costs.”

blog comments powered by Disqus
  • Newsmakers: PCI

    Newsmakers: PCI

    Tim Wright, Editor||June 2, 2015
    PCI execs talk about the recent opening of the company’s new North American clinical facility, as well as other trends in the market

  • How Sterilization of Primary Packaging Influences the Results of E&L Studies

    How Sterilization of Primary Packaging Influences the Results of E&L Studies

    Thorsten Sogding, Daniel Canton, Daniel Haines, Uwe Rothhaar, SCHOTT Pharma Services ||June 2, 2015
    As the demands that are being placed on the quality and stability of medications continue to increase, the interactions that take place between the primary packaging container and filled drug product are becoming increasingly important

  • Moore’s Law for More Health

    Moore’s Law for More Health

    Patrick Jordan , Encore Health Resources||June 2, 2015
    This year marks the semicentennial anniversary of a prediction about exponential growth and productivity